Рынок биопрепаратов Азиатско-Тихоокеанского региона – тенденции отрасли и прогноз до 2030 года

Настройте свой отчет Настройте свой отчет Купить сейчас Купить сейчас Бесплатный пример отчета Бесплатный пример отчета
Дом Pharmaceutical Asia Pacific Biologics Market
Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок биопрепаратов Азиатско-Тихоокеанского региона – тенденции отрасли и прогноз до 2030 года

  • Pharmaceutical
  • Published Report
  • Jan 2023
  • Asia-Pacific
  • 350 Pages
  • Количество таблиц: 207
  • Количество рисунков: 48
Купить сейчасКупить сейчас

Asia Pacific Biologics Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Diagram Прогнозируемый период
 2024 –2030
Diagram Размер рынка (базовый год)
 МИЛЛИОН ДОЛЛАРОВ США
Запрос
Diagram Размер рынка (прогнозируемый год)
 USD 141,276.35
Diagram CAGR
 %
Diagram Основные игроки рынка
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Запрос на разблокировку

>Рынок биологических препаратов Азиатско-Тихоокеанского региона по классу (ингибиторы фактора некроза опухоли-Α (ФНО), ингибиторы В-клеток, ингибиторы интерлейкина , селективные модуляторы костимуляции (абатацепт) и другие), типу (моноклональные антитела (МАБ), терапевтические белки, вакцины, клеточные биопрепараты, генные биопрепараты и другие), способу введения (инъекции и инфузии), применению (онкология, аутоиммунные заболевания, диабет, инфекционные заболевания, сердечно-сосудистые заболевания, офтальмологические состояния, дерматологические заболевания и другие), исходному материалу (люди, культура клеток птиц, дрожжи, бактерии, культура клеток насекомых, трансгеники и другие), конечному пользователю (больницы, специализированные клиники, академические и научно-исследовательские институты и другие), каналу сбыта (прямой тендер, розничная торговля Продажи и сторонняя дистрибуция). Тенденции отрасли и прогноз до 2030 года.

Азиатско-Тихоокеанский рынок биопрепаратов

Анализ и понимание рынка биологических препаратов в Азиатско-Тихоокеанском регионе

Биологические препараты — это препараты, производимые из живых организмов или некоторых компонентов живых организмов. Эти препараты могут быть получены из различных биологических источников, включая людей, культуру клеток птиц, дрожжи , бактерии и культуру клеток насекомых среди прочих. Эти препараты включают терапевтические белки, моноклональные антитела и вакцины . Эти препараты могут использоваться для лечения различных типов хронических заболеваний, включая рак, воспалительные заболевания, метаболические заболевания, сердечно-сосудистые заболевания и инфекционные заболевания .

Азиатско-Тихоокеанский рынок биопрепаратов

Азиатско-Тихоокеанский рынок биопрепаратов

Ожидается, что рынок биопрепаратов в Азиатско-Тихоокеанском регионе будет расти в прогнозируемый период с 2023 по 2030 год. По данным Data Bridge Market Research, среднегодовой темп роста рынка составит 11,5% в прогнозируемый период с 2023 по 2030 год, и ожидается, что к 2030 году его объем достигнет 141 276,35 млн долларов США.

Отчет Метрика

Подробности

Прогнозируемый период

2023-2030

Базовый год

2022

Исторический год

2021 (можно настроить на 2020-2016)

Количественные единицы

Доход в млн. долл. США

Охваченные сегменты

По классу (ингибиторы фактора некроза опухоли-Α (ФНО), ингибиторы В-клеток, ингибиторы интерлейкинов, селективные модуляторы костимуляции (абатацепт) и другие), типу ( моноклональные антитела (МАТ), терапевтические белки, вакцины, клеточные биопрепараты, генные биопрепараты и другие), способу введения (инъекции и инфузии), применению (онкология, аутоиммунные заболевания, диабет, инфекционные заболевания, сердечно-сосудистые заболевания, офтальмологические состояния, дерматологические заболевания и другие), исходному материалу (люди, культура клеток птиц, дрожжи, бактерии, культура клеток насекомых, трансгеники и другие), конечному пользователю (больницы, специализированные клиники, академические и научно-исследовательские институты и другие), каналу распространения (прямые торги, розничные продажи и распространение третьими лицами).

Страны, охваченные

Китай, Япония, Индия, Австралия, Южная Корея, Сингапур, Малайзия, Индонезия, Таиланд, Филиппины, Вьетнам и остальные страны Азиатско-Тихоокеанского региона.

Market Players Covered

AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics, and YL Biologics among others.

Market Definition

Biologics are the drugs produced from living organisms or some components of living organisms that have several advantages compared to other drug types, including small molecules. These are very much target-specific which has enhanced the demand among healthcare professionals. Moreover, the side effects caused are mostly related to exaggerated pharmacological effects, leading to mild health effects. Biologic drugs have also been proven to hold high potential for several therapeutic areas and have revolutionized treatments of several serious illnesses. For instance, Rituximab (chimeric monoclonal antibody) has significantly improved non-Hodkings lymphoma.

The major factor that drives the market growth is the rise in the prevalence of chronic diseases such as diabetes and cancer in developing countries. Furthermore, rise in initiatives by governments and surge in research for new biologics drugs are some of the factors that boost the market growth. However, lack of awareness about healthcare in developing countries is a major factor that restrains the market growth. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities for market expansion in the forecast period.

Asia-Pacific Biologics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

  • Rising prevalence of chronic diseases such as diabetes and cancers

Chronic diseases are one of the biggest healthcare concerns in the world, claiming an estimated 40 million lives every year, 8.5 million of whom reside in Asia. In Asia-Pacific, cardiovascular diseases, diabetes, cancer, and chronic respiratory conditions are among the most common chronic diseases. This is primarily driven by aging populations and poor lifestyle choices such as the lack of physical activity and tobacco & alcohol consumption.

  • Changes in lifestyle

Lifestyle diseases share risk factors similar to prolonged exposure to three modifiable lifestyle behaviors, smoking, unhealthy diet, and physical inactivity, and result in the development of chronic diseases, specifically heart disease, stroke, diabetes, obesity, metabolic syndrome, Chronic Obstructive Pulmonary Disease (COPD), and some types of cancer.

  • Recent advancements in biologics

Delivery by injection is the most convenient method for biologics delivery. It is not always ideal. This is primarily because of the pharmacokinetics of biologics, which means they are rapidly cleared from systemic circulation.

Co-formulation of therapeutics is an emerging strategy that aims to capitalize on advances in therapeutic effects observed through the co-administration of biologics.

RESTRAINTS

  • Complex manufacturing process of biologics

Biologics drugs are highly complex molecules produced by living cells through a multistep manufacturing process. The key characteristics of these molecules, known as Critical Quality Attributes (CQAs), can vary based on post-translational modifications that occur in the cellular environment or during the manufacturing process. The complexity of the manufacturing process leads to several defaults. Thus, the complex manufacturing process of biologics is acting as a major restraining factor for market growth.

  • Adverse side-effects of biologics

Like standard pharmaceuticals, biological treatments can cause adverse drug reactions. They can cause allergic reactions similar to the ways these drugs can. But they can also cause problems due to the way biologics interact with the immune system. They can also sometimes cause specific issues with various organ systems in the body.

Some of the side effects associated with biologics are:

  • Injection site reactions
  • Infusion reactions

Usually, these reactions are mild. However, sometimes they may be more severe such as hypersensitivity reactions, and require medical intervention.

Thus, adverse side effects of biologics treatment act as a restraint for market growth.

Азиатско-Тихоокеанский рынок биопрепаратов

OPPORTUNITIES

  • Rising healthcare expenditure

Across the globe, R&D activities are escalating owing to public health expenditure with economic performance. At the same time, the healthcare industry ranks second among all industries regarding R&D. Rising healthcare expenditure can result in better provision of R&D opportunities. That results in the anticipated upsurging demand for various cancer diagnostics.

  • Strategic initiatives by market players

An increase in the burden of various types of diseases such as cancers, diabetes, and cardiovascular diseases across Asia-Pacific, coupled with the rise in the geriatric population, has created more demand for biologics. The main aim is to improve health management in biologics for quality care with convenient application. Hence, major market players are focusing on fulfilling the demand for biologics and spending a noticeable amount on better products.

Thus, these strategic product launches, acquisitions, and mergers by major companies in the biologics market have opened up opportunities for companies in Asia. This strategy is allowing the companies to strengthen their footprints in the market.

  • Surge in healthcare expenditure

Healthcare expenditure has increased across Asia-Pacific region, as the disposable income of people across Asia is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking initiatives by accelerating healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare organizations to improve their treatment facilities for the usage of biologics.

  • Growing number of biopharmaceutical contract manufacturing companies in Asia

The biopharmaceutical contract manufacturing market is growing essentially due to the increasing demand for biologics and increasing outsourcing by pharmaceutical companies in Asia-Pacific. Increasing competition in the industry is likely to damage the market growth in the coming years. Additionally, robust advancements in R&D activities, emerging markets, and consolidation in the pharmaceutical CMO industry are likely to increase the growth of biopharmaceutical contract manufacturing companies during the forecast period.

The growing number of biopharmaceutical contract manufacturing companies leads to the development of new products via rigorous research to treat various diseases. Thus, this acts as an opportunity for market growth.

CHALLENGE

  • Stringent regulatory policies

Regulation of drugs plays a significant role in healthcare. Achieving the requisite approval for the legal selling of medical devices or medications in such jurisdictions can entail substantial financial expenditure, which could take months or years to complete. If these constraints are not understood or taken into account, delays can seriously jeopardize the likelihood of success in a highly competitive market. The biologics such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins among others are of significant importance for treating various diseases. But their approval and marketing in multiple regions across Asia require a meeting of stringent regulatory standards and acceptance by various regulatory bodies.

Thus, the above-mentioned stringent regulations and policies for approving the complicated nature of biologics act as a challenge to market growth.

Post-COVID-19 Impact on Asia-Pacific Biologics Market

The COVID-19 pandemic had somewhat negative impact on the biologics market. Due to the pandemic, new norms and regulations were imposed, such as social distancing and lockdown to prevent the spread of virus. As a result, people all over the world were forced to stay at home. This stay-at-home led to a decrease in the consumption of biologics, which further led to a decrease in the demand for biologics.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the quality of biologics existing in the market.

Recent Developments

Many product launches and agreements are also initiated by companies worldwide which are accelerating the market growth.

  • In November 2021, Biocon launched Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in collaboration with Viatris Inc. The new product launch helped patients control high blood sugar in adults and pediatric patients suffering from diabetes 1 and diabetes 2.
  • In December 2019, Bharat Biotech launched ROTAVAC 5D-lowest dose volume rotavirus vaccine across the world. The product launch was developed in partnership with the Department of Biotechnology, Government of India.

Asia-Pacific Biologics Market Scope

Asia-Pacific biologics market is segmented into seven notable segments based on class, type, route of administration, application, source material, end user, and distribution channel.

By Class

  • Tumor Necrosis Factor-Α (TNF) Inhibitors
  • B-Cell Inhibitors
  • Interleukin Inhibitors
  • Selective Co-Stimulation Modulators (Abatacept)
  • Others

Based on class, the market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others.

By Type

  • Monoclonal Antibodies (mABs)
  • Therapeutic Proteins
  • Vaccines
  • Cellular Based Biologics
  • Gene Based Biologics
  • Other

Based on type, the market is segmented into monoclonal antibodies (mABs), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and other.

By Route of Administration

  • Injection
  • Infusion

Based on route of administration, the market is segmented into injection, and infusion.

By Application

  • Oncology
  • Autoimmune Diseases
  • Diabetes
  • Infectious Diseases
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Dermatological Diseases
  • Others

Based on application, the market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others.

By Source Material

  • Humans
  • Avian Cell Culture
  • Yeast
  • Bacteria
  • Insects Cell Culture
  • Transgenics
  • Others

Based on source material, the market is segmented into humans, avian cell culture, yeast, bacteria, insect cell culture, transgenics, and others.

By End User

  • Hospital
  • Specialty Clinics
  • Academics and Research Institutes
  • Others

В зависимости от конечного пользователя рынок сегментируется на больницы, специализированные клиники, академические и научно-исследовательские институты и т. д.

Канал распространения

  • Прямой тендер
  • Розничные продажи
  • Распространение третьими лицами

По каналу сбыта рынок сегментируется на прямые торги, розничные продажи и дистрибуцию через третьих лиц.

Азиатско-Тихоокеанский рынок биопрепаратов

Региональный анализ/информация о рынке биопрепаратов в Азиатско-Тихоокеанском регионе

Проведен анализ рынка биологических препаратов в Азиатско-Тихоокеанском регионе и предоставлена ​​информация о размере рынка с учетом страны, класса, типа, пути введения, области применения, исходного материала, конечного пользователя и канала сбыта.

В 2022 году Азиатско-Тихоокеанский регион рос из-за растущей распространенности хронических заболеваний, таких как диабет и рак. Ожидается, что Китай будет доминировать на рынке из-за последних достижений в области биопрепаратов.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, заменяющие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность брендов Азиатско-Тихоокеанского региона и их проблемы, связанные с большой или малой конкуренцией со стороны местных и отечественных брендов, а также влияние каналов продаж.

Анализ конкурентной среды и доли рынка биологических препаратов в Азиатско-Тихоокеанском регионе

Конкурентная среда рынка биопрепаратов в Азиатско-Тихоокеанском регионе содержит подробную информацию о конкуренте. Включены следующие сведения: обзор компании, финансовые показатели компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, испытания продуктов, одобрения продуктов, патенты, широта и дыхание продукта, доминирование приложений и кривая жизненной линии технологий. Приведенные выше данные относятся только к фокусу компании на рынке.

Некоторые из основных игроков, работающих на этом рынке: AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., WuXi Biologics и YL Biologics и другие.

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of Asia-Pacific biologics market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. class LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET application COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
    1. Pestel's ANALYSIS
    2. Porter’s five forces
    3. Epidemiology
  5. Pipeline analysis
  6. Asia-Pacific Biologics Market: Laws and regulations
  7. market overview
    1. DRIVERS
      1. INCREASE IN PREVALENCE OF CHRONIC DISEASES SUCH AS DIABETES AND CANCERS
      2. CHANGES IN LIFESTYLE
      3. RECENT ADVANCEMENTS IN BIOLOGICS
    2. RESTRAINTS
      1. COMPLEX MANUFACTURING PROCESS OF BIOLOGICS
      2. ADVERSE SIDE-EFFECTS OF BIOLOGICS
    3. OPPORTUNITIES
      1. RISE IN HEALTHCARE EXPENSES
      2. STRATEGIC INITIATIVES BY MARKET PLAYERS
      3. surge in healthcare expenditure
      4. GROWING NUMBER OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING COMPANIES IN ASIA
    4. CHALLENGE
      1. STRINGENT REGULATORY POLICIES
  8. COVID-19 IMPACT ON Asia-Pacific biologics Market
    1. impact on price
    2. impact on demand
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISIONS of Government and MANUFACTURERS
    5. Conclusion
  9. Asia-Pacific biologics market, BY class
    1. overview
    2. Tumor Necrosis Factor-Α (TNF) Inhibitors
      1. Adalimumab
      2. Certolizumab
      3. Etanercept
      4. Infliximab
      5. Others
    3. B-Cell Inhibitors
      1. Belimumab
      2. Rituximab
      3. others
    4. Interleukin Inhibitors
      1. Anakinra
      2. Canakinumab
      3. Ixekizumab
      4. Secukinumab
      5. Tocilizumab
      6. Ustekinumab
      7. Others
    5. Selective Co-Stimulation Modulators (Abatacept)
    6. Others
  10. Asia-Pacific biologics market, BY route of administration
    1. overview
    2. INjECTION
    3. infusion
  11. Asia-Pacific biologics market, BY drug classification
    1. overview
    2. Branded Drugs
    3. generic drugs
  12. Asia-Pacific biologics market, BY source material
    1. overview
    2. Bacteria
    3. Avian Cell Culture
    4. Humans Cell Lines
    5. Yeast
    6. Insects Cell Culture
    7. Transgenics
  13. asia-pacific biologics MARKET, By type
    1. overview
    2. Monoclonal Antibodies (Mabs)
      1. Anti-Cancer Mabs
      2. Immunological Mabs
      3. Anti-Infective Monoclonal Antibodies (Mabs)
      4. Cardiovascular And Cerebrovascular Mabs
      5. Neuropharmacological Mabs
      6. Others Mabs
    3. Therapeutic Proteins
      1. Metabolic Disorders Therapeutic Proteins
      2. Cancer Therapeutic Proteins
      3. Cardiovascular Therapeutic Proteins
      4. Immunological Therapeutic Proteins
      5. Others Therapeutic Proteins
    4. Vaccines
      1. Anti-Infective Vaccines
      2. Autoimmunity Vaccines
      3. others
    5. cellular bassed biologics
    6. gene based biologics
    7. others
  14. asia-pacific biologics MARKET, By application
    1. overview
    2. oncology
      1. Breast Cancer
      2. Lung Cancer
      3. Leukemia
      4. Ovarian Cancer
      5. Non-Hodgkin Lymphoma
      6. Prostate Cancer
      7. Colorectal Cancer
      8. Others
    3. Infectious Diseases
    4. Autoimmune Diseases
      1. Rheumatoid Arthritis
      2. Systemic Lupus Erythematous
      3. Systemic Sclerosis
      4. Crohn’s Disease
      5. Sjogren's Syndrome
      6. Multiple Sclerosis
      7. Pernicious Anemia
      8. Others
    5. Diabetes
    6. Cardiovascular Diseases
    7. Ophthalmic Conditions
    8. Dermatological Diseases
    9. others
  15. asia-pacific biologics MARKET, By end user
    1. overview
    2. Hospitals
    3. Specialty Clinics
    4. Others
  16. asia-pacific biologics MARKET, By distribution channel
    1. overview
    2. hospital pharmacies
    3. retail pharmacies
    4. online Pharmacies
  17. ASIA-PACIFIC biologics market, By Country
    1. Asia-Pacific
      1. China
      2. japan
      3. India
      4. Australia
      5. South Korea
      6. Singapore
      7. Malaysia
      8. INDONESIA
      9. THAILAND
      10. Philippines
      11. VIETNAM
      12. REST OF ASIA-PACIFIC
  18. Asia-Pacific Biologics market: COMPANY landscape
    1. company share analysis: Asia-Pacific
  19. swot analysis
  20. company profile
    1. F. Hoffmann-La Roche Ltd
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    2. pfizer Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. MERGER
    3. bristol-meyers squibb company
      1. COMPANY SNAPSHOt
      2. Revenue analysis
      3. product portfolio
      4. recent developments
    4. MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. GLAXOSMITHKLINE PLC
      1. COMPANY SNAPSHOt
      2. Revenue analysis
      3. product portfolio
      4. recent development
    6. abbvie Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. FDA APPROVAL:
    7. AGC Biologics
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENTS
    8. Bharat Biotech
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENTS
    9. Biocon
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENTs
    10. BioDiem
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. Technology Portfolio
      4. RECENT DEVELOPMENT
    11. catalent, inc.
      1. COMPANY SNAPSHOt
      2. revenue analysis
      3. product portfolio
      4. recent development
    12. Celltrion Healthcare Co.,Ltd.
      1. COMPANY SNAPSHOt
      2. Revenue analysis
      3. product portfolio
      4. recent development
    13. Johnson & Johnson Services, Inc.
      1. COMPANY SNAPSHOt
      2. revenue analysis
      3. product portfolio
      4. recent development
    14. Biogen
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENT
    15. BeiGene
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENTS
    16. chime biologics
      1. COMPANY SNAPSHOt
      2. SERVICE portfolio
      3. recent development
    17. Cipla Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    18. Evotec
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
      5. ACQUISITION
    19. FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENT
    20. Innovent
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENTS
    21. Intas Pharmaceutical Ltd.
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENT
    22. Ipsen Pharma
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENT
    23. KM Biologics (A Subsidiary of Meiji Holdings Co., Ltd.)
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENT
    24. nbhl ltd.
      1. COMPANY SNAPSHOt
      2. product portfolio
      3. recent development
    25. Panacea Biotec
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfolio
      4. RECENT DEVELOPMENT
    26. Qilu Pharmaceutical Co., Ltd.
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENT
    27. SAMSUNG biologics
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. ACQUISITION
    28. serum institute of india pvt. ltd.
      1. COMPANY SNAPSHOt
      2. product portfolio
      3. recent developments
    29. Shanghai Henlius Biotech, Inc.
      1. COMPANY SNAPSHot
      2. Revenue analysis
      3. product Portfolio
      4. RECENT DEVELOPMENTS
    30. Teva Pharmaceutical Industries Ltd.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. EXPANSION:
    31. wuxi biologics
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
      5. LICENSE:
    32. YL Biologics
      1. COMPANY SNAPSHot
      2. product Portfolio
      3. RECENT DEVELOPMENT
  21. questionnaire
  22. related reports

Список таблиц

TABLE 1 pipeline analysis

TABLE 2 REGULATION imposed by several regulatory agencies in different countRIes

TABLE 3 Asia-Pacific Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 4 Asia-Pacific Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 5 Asia-Pacific B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 6 Asia-Pacific Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 7 Asia-Pacific Biologics MARKET, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 8 Asia-Pacific Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 9 Asia-Pacific biologics Market, By Source material, 2020-2029 (USD Million)

TABLE 10 Asia-Pacific biologics Market, By type , 2020-2029 (USD Million)

TABLE 11 Asia-Pacific Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 12 Asia-Pacific Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 13 Asia-Pacific Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 14 Asia-Pacific Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 15 Asia-Pacific Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 16 Asia-Pacific Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 17 Asia-Pacific Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 18 Asia-Pacific Biologics Market, By Distribution Channel, 2020-2029 (USD Million)

TABLE 19 Asia-Pacific biologics market, By COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 China Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 21 China Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 22 China B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 23 China Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 24 China Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 25 China Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 26 China Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 27 China Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 28 China Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 29 China Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 30 China Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 31 China Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 32 China Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 33 China Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 34 China Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 35 China Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 36 Japan Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 37 Japan Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 38 Japan B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 39 Japan Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 40 Japan Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 41 Japan Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 42 Japan Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 43 Japan Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 44 Japan Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 45 Japan Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 46 Japan Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 47 Japan Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 48 Japan Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 49 Japan Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 50 Japan Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 51 Japan Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 52 India Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 53 India Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 54 India B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 55 India Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 56 India Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 57 India Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 58 India Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 59 India Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 60 India Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 61 India Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 62 India Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 63 India Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 64 India Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 65 India Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 66 India Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 67 India Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 68 Australia Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 69 Australia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 70 Australia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 71 Australia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 72 Australia Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 73 Australia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 74 Australia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 75 Australia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 76 Australia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 77 Australia Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 78 Australia Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 79 Australia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 80 Australia Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 81 Australia Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 82 Australia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 83 Australia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 84 South Korea Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 85 South Korea Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 86 South Korea B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 87 South Korea Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 88 South Korea Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 89 South Korea Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 90 South Korea Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 91 South Korea Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 92 South Korea Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 93 South Korea Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 94 South Korea Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 95 South Korea Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 96 South Korea Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 97 South Korea Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 98 South Korea Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 99 South Korea Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 100 Singapore Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 101 Singapore Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 102 Singapore B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 103 Singapore Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 104 Singapore Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 105 Singapore Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 106 Singapore Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 107 Singapore Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 108 Singapore Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 109 Singapore Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 110 Singapore Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 111 Singapore Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 112 Singapore Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 113 Singapore Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 114 Singapore Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 115 Singapore Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 116 Malaysia Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 117 Malaysia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 118 Malaysia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 119 Malaysia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 120 Malaysia Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 121 Malaysia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 122 Malaysia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 123 Malaysia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 124 Malaysia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 125 Malaysia Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 126 Malaysia Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 127 Malaysia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 128 Malaysia  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 129 Malaysia Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 130 Malaysia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 131 Malaysia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 132 Indonesia Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 133 Indonesia Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 134 Indonesia B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 135 Indonesia Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 136 Indonesia Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 137 Indonesia Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 138 Indonesia Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 139 Indonesia Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 140 Indonesia Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 141 Indonesia Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 142 Indonesia Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 143 Indonesia Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 144 Indonesia  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 145 Indonesia Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 146 Indonesia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 147 Indonesia Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 148 Thailand Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 149 Thailand Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 150 Thailand B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 151 Thailand Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 152 Thailand Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 153 Thailand Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 154 Thailand Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 155 Thailand Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 156 Thailand Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 157 Thailand Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 158 Thailand Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 159 Thailand Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 160 Thailand  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 161 Thailand Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 162 Thailand Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 163 Thailand Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 164 Philippines Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 165 Philippines Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 166 Philippines B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 167 Philippines Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 168 Philippines Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 169 Philippines Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 170 Philippines Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 171 Philippines Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 172 Philippines Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 173 Philippines Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 174 Philippines Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 175 Philippines Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 176 Philippines  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 177 Philippines Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 178 Philippines Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 179 Philippines Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 180 Vietnam Biologics Market, BY Class, 2020-2029 (USD Million)

TABLE 181 Vietnam Tumor Necrosis Factor-Α (TNF) Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 182 Vietnam B-Cell Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 183 Vietnam Interleukin Inhibitors in Biologics Market, By Class, 2020-2029 (USD Million)

TABLE 184 Vietnam Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 185 Vietnam Monoclonal Antibodies (Mabs) in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 186 Vietnam Therapeutic Proteins in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 187 Vietnam Vaccines in Biologics Market, BY Type, 2020-2029 (USD Million)

TABLE 188 Vietnam Biologics Market, BY Route Of Administration, 2020-2029 (USD Million)

TABLE 189 Vietnam Biologics Market, By Drug Classification, 2020-2029 (USD Million)

TABLE 190 Vietnam Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 191 Vietnam Oncology in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 192 Vietnam  Autoimmune Diseases in Biologics Market, By Application, 2020-2029 (USD Million)

TABLE 193 Vietnam Biologics Market, By Source Material, 2020-2029 (USD Million)

TABLE 194 Vietnam Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 195 Vietnam Biologics Market, By End User, 2020-2029 (USD Million)

TABLE 196 Rest of Asia-Pacific Biologics Market, BY Class, 2020-2029 (USD Million)

Список рисунков

FIGURE 1 Asia-Pacific biologics market: segmentation

FIGURE 2 Asia-Pacific biologics market: data triangulation

FIGURE 3 Asia-Pacific biologics market: DROC ANALYSIS

FIGURE 4 Asia-Pacific biologics market : REGIONAL vs country MARKET ANALYSIS

FIGURE 5 Asia-Pacific biologics market : COMPANY RESEARCH ANALYSIS

FIGURE 6 Asia-Pacific biologics market : multivariate modelling

FIGURE 7 Asia-Pacific biologics market: INTERVIEW DEMOGRAPHICS

FIGURE 8 Asia-Pacific biologics market: DBMR MARKET POSITION GRID

FIGURE 9 Asia-Pacific biologics market: vendor share analysis

FIGURE 10 Asia-Pacific biologics market: application type COVERAGE GRID

FIGURE 11 Asia-Pacific biologics market: SEGMENTATION

FIGURE 12 AN Increase in prevalEnce of chronic diseases such as diabetes and cancers and recent advancements in biologics are expected to drive THE Asia-Pacific biologics market IN THE FORECAST PERIOD of 2022 to 2029

FIGURE 13 tumor necrosis factor-A (TNF) Inhibitors segment is expected to account for the largest share of the Asia-Pacific biologics market in 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITES, AND CHALLENGE OF ASIA-PACIFIC BIOLOGICS MARKET

FIGURE 15 Asia-Pacific biologics market: BY class, 2021

FIGURE 16 ASIA-PACIFIC BIOLOGICS MARKET, BY class, 2020-2029 (USD MILLION)

FIGURE 17 ASIA-PACIFIC BIOLOGICS MARKET: BY class, CAGR (2022-2029)

FIGURE 18 ASIA-PACIFIC BIOLOGICS MARKET: BY class, LIFELINE CURVE

FIGURE 19 Asia-Pacific biologics market: BY route of administration, 2021

FIGURE 20 ASIA-PACIFIC BIOLOGICS MARKET, BY route of administration, 2020-2029 (USD MILLION)

FIGURE 21 ASIA-PACIFIC BIOLOGICS MARKET: BY route of administration, CAGR (2022-2029)

FIGURE 22 ASIA-PACIFIC BIOLOGICS MARKET: BY route of administration, LIFELINE CURVE

FIGURE 23 Asia-Pacific biologics market: BY drug classification, 2021

FIGURE 24 ASIA-PACIFIC BIOLOGICS MARKET, BY drug classification, 2020-2029 (USD MILLION)

FIGURE 25 ASIA-PACIFIC BIOLOGICS MARKET: BY drug classification, CAGR (2022-2029)

FIGURE 26 ASIA-PACIFIC BIOLOGICS MARKET: BY drug classification, LIFELINE CURVE

FIGURE 27 Asia-Pacific biologics market: BY source material, 2021

FIGURE 28 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, 2020-2029 (USD MILLION)

FIGURE 29 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, CAGR (2022-2029)

FIGURE 30 ASIA-PACIFIC BIOLOGICS MARKET: BY source material, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC BIOLOGICS MARKET: By type, 2021

FIGURE 32 ASIA-PACIFIC BIOLOGICS MARKET: By type, 2020-2029 (USD MILLION)

FIGURE 33 ASIA-PACIFIC BIOLOGICS MARKET: By type, CAGR (2022-2029)

FIGURE 34 ASIA-PACIFIC BIOLOGICS MARKET: By type, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC BIOLOGICS MARKET: By application, 2021

FIGURE 36 ASIA-PACIFIC BIOLOGICS MARKET: By application, 2020-2029 (USD MILLION)

FIGURE 37 ASIA-PACIFIC BIOLOGICS MARKET: By application, CAGR (2022-2029)

FIGURE 38 ASIA-PACIFIC BIOLOGICS MARKET: By application, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC BIOLOGICS MARKET: By end user , 2021

FIGURE 40 ASIA-PACIFIC BIOLOGICS MARKET: By end USER, 2020-2029 (USD MILLION)

FIGURE 41 ASIA-PACIFIC BIOLOGICS MARKET: By end user , CAGR (2022-2029)

FIGURE 42 ASIA-PACIFIC BIOLOGICS MARKET: By end user , LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, 2021

FIGURE 44 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, 2020-2029 (USD MILLION)

FIGURE 45 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, CAGR (2022-2029)

FIGURE 46 ASIA-PACIFIC BIOLOGICS MARKET: By distribution channel, LIFELINE CURVE

FIGURE 47 Asia-Pacific biologics market: SNAPSHOT (2021)

FIGURE 48 Asia-Pacific biologics market: BY COUNTRY (2021)

FIGURE 49 Asia-Pacific biologics market: BY COUNTRY (2022 & 2029)

FIGURE 50 Asia-Pacific biologics market: BY COUNTRY (2021 & 2029)

FIGURE 51 Asia-Pacific biologics market: BY CLASS (2022-2029)

FIGURE 52 ASIA-PACIFIC Biologics market: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

The Asia-Pacific Biologics Market will be worth USD 141,276.35 million in the forecast period by 2030.
The Asia-Pacific Biologics Market growth rate is 11.5% in the forecast period by 2030.
Changes in lifestyle, Recent advancements in biologics, and the Rising prevalence of chronic diseases such as diabetes and cancers are the growth drivers of the Asia-Pacific Biologics Market.
The class, type, route of administration, application, source material, end user, and distribution channel are the factors on which the Asia-Pacific Biologics Market research is based.
Major companies in the Asia-Pacific Biologics Market are AbbVie Inc., AGC Biologics, BeiGene, Bharat Biotech, BioDiem, Biogen, Biocon, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Healthcare Co., Ltd., CHIME BIOLOGICS, Cipla Inc., F. Hoffmann-La Roche Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., GlaxoSmithKline plc., Innovent, Intas Pharmaceutical Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., KM Biologics, MERCK & CO., INC., NBHL ltd., Panacea Biotec, Pfizer Inc., Qilu Pharmaceutical Co., Ltd., Serum Institute of India Pvt. Ltd., Shanghai Henlius Biotech, Inc.

Просмотр связанных страниц

Banner